Although several reports have shown improved patient survival using DST-guided treatment in different cancers,[21] [24] current DST platforms have a limited ability to study the immune system and tumor microenvironment. Combining genomics and functional data further refines precision therapy, enhancing appropriate drug combination selection - even lacking actionable biomarkers - and ultimately improving clinical outcomes for pediatric patients with relapsed and/or recurrent tumors, establishing a new treatment paradigm in pediatric cancer. Nat Med; 23: 1028-1035, 2017 3 Brodin BA, Wennerberg K, Lidbrink E, et al: Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. Treatments for rhabdomyosarcoma (RMS) including sclerosing and spindle cell rhabdomyosarcoma (SRMS) remains challenging. [Extracted from the article]